BHCM
REGN icon

Boulder Hill Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Boulder Hill Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-900
Closed -$620K – 204
2022
Q3 		$620K Buy
+900
New +$566K 0.47% 47

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boulder Hill Capital Management's REGN Position: Q4 2022 in Review

Boulder Hill Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 900 shares — an estimated $620K sold.

Boulder Hill Capital Management first reported a position in REGN in Q3 2022 and held it in 1 quarter. The position peaked at $620K in Q3 2022. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Boulder Hill Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 900 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $620K.
  • Boulder Hill Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Regeneron Pharmaceuticals position peaked at $620K in Q3 2022.
  • 1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Boulder Hill Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.